In this whole animal study, we demonstrate that canonical NF-κB-mediated drug resistance—through upregulation of glucuronidation pathway activity—is an emergent property of CRC tumours that combine high WNT activity with oncogenic Ras. The gene discussed is NFKB1; the disease is colorectal carcinoma.